Shenyi Yin

Main text (Cell 187, 7470–7491.e1–e20; December 26, 2024) Since publication of the article, the authors have become aware of two figure display errors and one typographical error. These changes do not affect the results, interpretation, or conclusions of the article. In Figure 6B, the representative image displayed in the Ctr group Field #2 position was incorrect. The correct image has now been inserted.

Abstract Decreased cross-presentation by antigen-presenting cells induces the scarcity of tumour-reactive T cells within the tumour bed, rendering in situ T cell rejuvenation through immunogenicity reprogramming highly desirable yet challenging1,2,3. Here we developed an intratumoural vaccination chimera (iVAC) to reprogram tumour cells into an antigen-presenting state (APC-like tumour cells) with restored anti-tumour immunity.

Study design and patients This is an observational trial. The aim of the study was to assess the feasibility and predictive value of a standardized PTC-based test to differentiate efficacy of the patients' clinical drug regimens. The study was conducted at Peking University Cancer Hospital and was approved by the local ethical review board. The study protocol was in accordance with the Declaration of Helsinki, Chinese law and Good Clinical Practice.